Sanofi slides J&J’s E. coli vaccine into late-stage portfolio, betting $175M cash on development, commercialization pact
Sanofi has added a late-stage candidate to its vaccine franchise, paying J&J’s Janssen $175 million upfront to partner on a shot that will protect people …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
